Trial Profile
A Multicenter, Randomized, Pilot, Dose-Ranging Clinical Study to Evaluate Safety and Efficacy of TeaRx Xa Factor Direct Inhibitor Versus Enoxaparin as a Venous Thromboembolic Events (VTE) Prevention Following Total Knee Replacement
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs TRX 1-TeaRx (Primary) ; Enoxaparin sodium
- Indications Venous thromboembolism
- Focus Adverse reactions; Therapeutic Use
- Sponsors TeaRx
- 08 Jan 2014 New trial record